Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The RNA-induced silencing complex (RISC) is a multi-protein assembly that serves as the fundamental effector of the RNA interference (RNAi) pathway in eukaryotic cells (UniProt P98170). The core catalytic component of this complex is Protein Argonaute-2 (Ago2), a specialized endonuclease that utilizes small interfering RNAs (siRNAs) or microRNAs (miRNAs) as templates to identify complementary messenger RNA (mRNA) sequences. Upon binding to a target mRNA, the PIWI domain of Ago2 facilitates the site-specific cleavage of the transcript, leading to its rapid degradation and the subsequent silencing of the encoded protein. This mechanism is highly conserved and plays a critical role in regulating gene expression, defending against viral infections, and maintaining genomic stability. In modern medicine, RISC/Ago2 is the primary target for siRNA-based therapeutics, which are designed to hijack this endogenous machinery to selectively downregulate disease-causing genes. Approved drugs such as Patisiran and Inclisiran utilize this pathway to treat conditions ranging from hereditary amyloidosis to hypercholesterolemia by delivering synthetic siRNAs that load into the RISC (FDA Prescribing Information). However, therapeutic development must address challenges such as off-target effects, where the complex silences unintended genes, and the potential for saturating the cell's natural RNAi capacity.
RNA interference (RNAi) mediated by the sequence-specific cleavage of target mRNA by the endonuclease activity of Argonaute-2.
8 more in the full profile.
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein Argonaute-2 (AGO2) (AGO2).